1. Home
  2. SNPS vs SNY Comparison

SNPS vs SNY Comparison

Compare SNPS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synopsys Inc.

SNPS

Synopsys Inc.

HOLD

Current Price

$432.01

Market Cap

112.2B

Sector

Technology

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$50.29

Market Cap

119.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNPS
SNY
Founded
1986
1994
Country
United States
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.2B
119.4B
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
SNPS
SNY
Price
$432.01
$50.29
Analyst Decision
Buy
Buy
Analyst Count
15
4
Target Price
$556.33
$61.50
AVG Volume (30 Days)
2.2M
2.2M
Earning Date
12-10-2025
10-24-2025
Dividend Yield
N/A
3.21%
EPS Growth
31.64
105.93
EPS
12.67
8.67
Revenue
$6,435,304,000.00
$53,890,648,839.00
Revenue This Year
$17.26
$2.37
Revenue Next Year
$37.38
$6.51
P/E Ratio
$56.47
$11.32
Revenue Growth
8.00
N/A
52 Week Low
$365.74
$44.62
52 Week High
$651.73
$60.12

Technical Indicators

Market Signals
Indicator
SNPS
SNY
Relative Strength Index (RSI) 57.38 51.27
Support Level $376.69 $49.14
Resistance Level $405.91 $50.61
Average True Range (ATR) 13.32 0.73
MACD 6.92 -0.13
Stochastic Oscillator 80.21 40.00

Price Performance

Historical Comparison
SNPS
SNY

About SNPS Synopsys Inc.

Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: